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Antimicrobial resistance (AMR) among both Gram-positive and 
Gram-negative bacteria has increased in recent years.[1] Bacteria in 
the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, Enterobacter spp.) account for two-thirds of all healthcare-
associated infections and have been shown to display high rates of 
AMR.[2] Gram-negative ESKAPE organisms are of concern owing 
to their multidrug-resistant phenotypes, which generally present 
clinicians with few treatment options.[3] Surveillance for AMR is 
pivotal to understanding the extent of resistance at individual facilities 
and at the national level. Surveillance reports provide guidance for 
antibiotic treatment at local and national levels. Surveillance is an 
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Background. In South Africa (SA), the National Department of Health has developed an Antimicrobial Resistance National Strategy 
Framework document to manage antimicrobial resistance (AMR). One of the strategic objectives is to optimise surveillance and early 
detection of AMR. At the National Institute for Communicable Diseases (NICD), an analysis of selected organisms and antimicrobial agents 
from both the public and the private sectors was conducted.
Objectives. The relevance of surveillance for AMR is increasingly recognised in the light of global action plans to combat resistance. In this 
report, we present an overview of ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, Enterobacter spp.) organisms and Escherichia coli reported from public and private sector laboratories in SA for 
the period 2016 - 2017.
Methods. Antimicrobial susceptibility testing (AST) profiles on selected ESKAPE organisms and E. coli isolated from blood cultures from 
the public and private sectors in 2016 and 2017 were analysed. AST data were extracted from a web-based electronic platform created by 
the NICD. Drug-bug combinations following the World Health Organization’s Global Antimicrobial Surveillance System guidelines were 
included in the analysis.
Results. A total of 28 920 ESKAPE organisms and E. coli were reported in 2016 and 32 293 in 2017 across the two health sectors. 
Proportions of some organisms differed between the two health sectors, such as E. coli (19% in the public sector and 36% in the private 
sector), A. baumannii (14% public and 4% private), P. aeruginosa (7% public and 11% private) and S. aureus (27% public and 17% private). 
Susceptibility data indicated changing patterns in both sectors towards an increase in non-susceptibility to carbapenems in K. pneumoniae 
(p<0.01). However, we demonstrated an increase in susceptibility to cloxacillin in S. aureus (p<0.01) in both sectors.
Conclusions. The key clinically important finding is the rapidly decreasing carbapenem susceptibility among Enterobacteriaceae reported 
in SA, irrespective of sector. In addition, the analysis provides information that could be used to monitor the effectiveness of interventions 
implemented at a national level under the guidance and direction of the national AMR framework.
S Afr Med J 2019;109(12):934-940. https://doi.org/10.7196/SAMJ.2019.v109i12.14079
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important strategy in the South African (SA) National Department of 
Health and features in the Antimicrobial Resistance National Strategy 
Framework document as one of the strategic objectives to optimise 
surveillance and early detection of AMR. At the National Institute for 
Communicable Diseases (NICD), an analysis of selected organisms 
and antimicrobial agents from both the public and the private health 
sectors was conducted.
Objectives
To describe the spectrum of selected ESKAPE organisms as well as 
Escherichia coli isolated from patients with bacteraemia reported 
from the two health sectors in SA and to compare their antimicrobial 
susceptibility testing (AST) profiles over a 2-year period.
Methods
Secondary data analysis was conducted from January 2016 to December 
2017. AST data were extracted from a secure web-based electronic 
platform created by the Surveillance Information Management Unit at 
the NICD. These data were available on the AMR dashboard from the 
NICD website (http://www.nicd.ac.za). The study population included 
all patients who had a blood culture submitted either to the public 
National Health Laboratory Service or to one of the four accredited 
private pathology laboratories (Ampath, Lancet Laboratories, PathCare 
and Vermaak and Partners). Positive blood cultures with any one of the 
ESKAPE organisms or E. coli were included in the analysis. A working 
group of the South African Society for Clinical Microbiology made 
a decision in 2015 not to include surveillance of Enterobacter spp. 
owing to concerns about lack of standardisation in the testing and 
reporting of susceptibility profiles between different laboratories. In 
line with the GERMS-SA laboratory-based surveillance programmes, 
duplicate isolates obtained from the same patient within 21 days were 
excluded in order to avoid bias due to over-representation of sicker 
patients undergoing multiple investigations. AST and interpretation of 
results were performed by individual laboratories according to current 
Clinical and Laboratory Standards Institute (CLSI) guidelines,[4] 
or European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) guidelines[5] at one private laboratory. There were only 
a few minor changes in the breakpoint interpretation in EUCAST 
during the 2 years of the study (for example, cefepime zone sizes 
were changed from 19 mm to 21 mm), and no changes in CLSI 
have been indicated for drug-bug combinations analysed in in this 
article. Data were omitted for hospitals that tested <30 organisms for 
a particular antimicrobial agent. In the secondary data analysis, AST 
results were grouped based on categorical data as provided by the 
submitting laboratories. Results were reported as susceptible or non-
susceptible, which includes the intermediate and resistant categories. 
Reporting of susceptibility profiles for drug-bug combinations was 
based on the Global Antimicrobial Surveillance System (GLASS) early 
implementation manual.[6] Absolute frequencies, percentages, bar 
charts and tables were used to describe the data. The χ2 test was used to 
compare differences among AST patterns over the 2-year period, with 
the level of significance set at p<0.05.
Results
A total of 28 920 ESKAPE organisms and E. coli were reported in 
2016 and 32 293 in 2017 across the two health sectors in SA. The 
proportion of E. coli was 19% in the public sector and 36% in the 
private sector, that of K. pneumoniae was 27% in the public sector and 
30% in the private sector, that of A. baumannii was 14% in the public 
sector and 4% in the private sector, that of P. aeruginosa was 7% in the 
public sector and 11% in the private sector, that of E. faecium was 8% 
in the public sector and 4% in the private sector, and that of S. aureus 
was 27% in the public sector and 17% in the private sector (Fig. 1).
Enterobacteriaceae
E. coli
The bacterial profile for E. coli reported over the 2-year period showed 
notable differences in the proportions across the two health sectors. 
For the public sector, the proportion was similar over the 2 years, 19% 
(3  981/20 630) in 2016 and 19% (4 085/21 124) in 2017. However, in the 
private sector, there was an increase in the proportion of reported E. coli 
from 34% (2 781/8 290) in 2016 to 37% (4 187/11 169) in 2017 (Fig. 1). 
Comparison of the AST profiles for the fluoroquinolone ciprofloxacin 
showed no change in the public sector (74%), but in the private sector 
there was a significant decrease in susceptibility from 69% to 65% 
(p<0.01). Although no significant changes were noted for the third-
generation cephalosporins cefotaxime/ceftriaxone and ceftazidime and 
the fourth-generation cephalosporin cefepime, higher susceptibility 
was noted for isolates reported from the private sector compared with 
the public sector. High proportions of isolates (≥99 %) reported from 
both health sectors were susceptible to the carbapenems ertapenem, 
imipenem and meropenem. No significant changes in susceptibility 
profiles were observed for the beta-lactam and beta-lactamase inhibitor 
piperacillin-tazobactam in either health sector (Table 1).
K. pneumoniae
The bacterial profile for K. pneumoniae reported over the 2-year 
period was similar for the two health sectors: 27% (5 533/20 630) in 
the public sector in 2016 and 26% (5 440/21 124) in 2017, and 30% 
(2 466/8 290) in the private sector in 2016 and 29% (3 204/11 169) 
in 2017 (Fig. 1). AST profiles for ciprofloxacin reported from both 
health sectors showed a significant decrease in susceptibility, from 
66% to 64% in the public sector (p=0.04) and from 60% to 54% in the 
private sector (p<0.01). Significant decreases in susceptibilities were 
noted for the carbapenems in both health sectors. In the public sector, 
ertapenem decreased from 96% to 92% (p<0.01), imipenem from 
95% to 91% (p<0.01) and meropenem from 94% to 91% (p<0.01), and 
in the private sector, ertapenem decreased from 85% to 77% (p<0.01), 
imipenem from 90% to 85% (p<0.01) and meropenem from 91% to 
86% (p<0.01). No significant changes in susceptibility to piperacillin-
tazobactam were noted for isolates reported from the public sector, 
but isolates reported from the private sector showed a significant 
decrease from 43% to 37% (p<0.01) (Table 2).
Non-fermentative Gram-negative bacteria
A. baumannii
The bacterial profile for A. baumannii reported over the 2-year period 
showed a ~10% difference in the proportion of isolates reported by 
the two health sectors: 13% (2 736/20 630) in 2016 and 15% (3 139/21 
124) in 2017 in the public sector and 4% (304/8 290) in 2016 and 
4% (458/11 169) in 2017 in the private sector (Fig. 1). A significant 
decrease in susceptibility to the aminoglycosides (amikacin from 
44% to 37% (p<0.01) and gentamicin from 32% to 23% (p<0.01)) 
was observed in isolates reported from the public sector. Although 
a decrease in susceptibility was noted for isolates reported from the 
private sector (amikacin from 63% to 57% (p=0.08) and gentamicin 
from 53% to 46% (p=0.06)), these differences were not significant 
(p≥0.05) (Table 3). Significant decreases in susceptibilities were noted 
for the carbapenems reported from both health sectors: imipenem 
from 27% to 19% (p<0.01) and meropenem from 25% to 19% (p<0.01) 
in the public sector and imipenem from 46% to 38% (p=0.03) and 
meropenem from 44% to 38% (p=0.09) in the private sector (Table 3).
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P. aeruginosa
The bacterial profile for P. aeruginosa reported over the 2-year 
period showed a ~5% difference in the proportion of isolates 
reported by the two health sectors. The absolute numbers of 
reported cases were approximately the same: 6% (1 197/20 630) in 
2016 and 7% (1  471/21  124) in 2017 in the public sector and 11% 
(914/8 290) in 2016 and 11% (1 256/11 169) in 2017 in the private 
sector (Fig. 1). A significant increase in susceptibility to ceftazidime 
from 79% to 84% was noted for isolates reported from the public 
sector (p<0.01). Isolates reported from the public sector showed no 
significant changes in susceptibility to imipenem and meropenem. 
However, a significant decrease in susceptibility was observed for 
isolates reported from the private sector: imipenem from 62% 
to 58% (p=0.04) and meropenem from 64% to 60% (p=0.03). 
Although isolates reported from the private sector displayed similar 
susceptibility patterns to piperacillin-tazobactam, isolates reported 
from the public sector showed a significant increase in susceptibility 
from 73% to 81% (p<0.01) (Table 4).
Gram-positive bacteria
E. faecium
The bacterial profile for E. faecium reported over the 2-year period 
showed notable differences in proportions across the two health 
sectors. For the public sector, the proportion was similar, 8% 
(1 669/20 630) in 2016 and 7% (1 565/21 124) in 2017, and was 
shown to be higher than in the private sector, where it was 4% 
(311/8 290) in 2016 and 3% (315/11 169) in 2017 (Fig. 1). Although 
a high proportion of isolates reported from both health sectors 
were susceptible to both vancomycin and teicoplanin, a significant 
decrease in susceptibility to teicoplanin was noted for isolates in the 
public sector, from 97% to 94% (p<0.01). No changes in susceptibility 
patterns were noted for linezolid during the 2 years (Table 5).
S. aureus
The bacterial profile for S. aureus reported over the 2-year period 
showed notable differences in the proportions across the two health 
sectors. For the public sector the proportion was similar, 27% 
(5  514/20 630) in 2016 and 26% (5 424/21 124) in 2017, and the 
figures were lower in the private sector, 18% (1 514/8 290) in 2016 
and 16% (1 749/11 169) in 2017 (Fig. 1). A significant increase in 
susceptibility to the penicillinase-stable penicillin cloxacillin was 
observed in both sectors, from 72% to 77% in the public sector 
(p<0.01) and from 74% to 85% in the private sector (p<0.01). 
A  general observation was that a greater proportion of cloxacillin-
susceptible S. aureus isolates was reported in the private sector 
compared with the public sector in 2017 (Table 6).
Discussion
This report describes and compares AST profiles for ESKAPE 
organisms and E. coli isolated from blood cultures over a 2-year 
period in the public and private health sectors in SA. The majority of 
isolates were reported from the public sector (71% (20 630/28 920) 
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Fig. 1. Bacterial profile for ESKAPE organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, Enterobacter spp.) and Escherichia coli identified from blood cultures from public and private health sectors in South Africa, 2016 - 2017.
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in 2016 and 65% (21 124/32 293) in 2017), demonstrating the public 
laboratory coverage of ~80% of the general population; however, this 
ratio still reflects under-utilisation of blood culture diagnostics in the 
public sector.
Gram-negative bacteria were reported more commonly than 
Gram-positive ones in both the public sector (65% (13 447/20 630) 
in 2016 and 67% (14 135/21 124) in 2017) and the private sector 
(78% (6 465/8 290) in 2016 and 82% (9 105/11 169) in 2017). We 
also observed a different bacterial profile for the two sectors. In 
the public sector, higher proportions of E. faecium, A. baumannii 
and S. aureus were reported, while in the private sector there 
were higher proportions of P. aeruginosa and E. coli. The present 
report only described the susceptibility profiles of organisms, and 
not demographic or clinical data. It was therefore not possible to 
determine the reasons for this difference. Possible causes may include 
differences in specimen-taking practices, differences in infection 
control practices and different patient populations.
In the Enterobacteriaceae group, E. coli showed no noteworthy 
differences in susceptibility profile in the public sector. However, a 
significant decrease in susceptibility to ciprofloxacin and amoxicillin-
clavulanic acid was observed in the private sector, possibly owing 
to excessive use of these agents in treatment of the most common 
urinary and respiratory infections.
K. pneumoniae demonstrated decreased susceptibility to many 
antibiotics (p<0.01) in both sectors, suggesting possible overuse 
of broad-spectrum antibiotics or lack of infection prevention and 
control. The most striking finding was a decrease in susceptibility to 
the carbapenems, with both sectors showing a significant difference 
just a year apart (p<0.01). This increase in carbapenem-resistant 
Enterobacteriaceae (CRE) is largely attributable to the increase in 
isolates harbouring carbapenemase-producing genes.[7] A number 
of factors may have influenced this change, including poor infection 
prevention and control measures targeting CRE, lack of effective 
antimicrobial stewardship programmes, or possible emergence of a 
successful clone.[8]
Antimicrobial susceptibility of A. baumannii indicated a significant 
decrease in susceptibility to aminoglycosides and carbapenems in the 
public sector, possibly owing to use of these agents in the treatment 
of infections by K. pneumoniae and other Enterobacteriaceae. In 
contrast, the only observed significant change in antimicrobial 
susceptibility of A. baumannii in the private sector was decreased 
susceptibility to the carbapenem imipenem.
Table 1. Antimicrobial susceptibility patterns of Escherichia coli isolates identified from blood cultures in South Africa, 2016 - 2017
    2016 2017  
Health sector Drug
Total 
isolates 
tested, N
Susceptible, 
n (%)
Total isolates 
tested, N Susceptible, n (%) p-value
Public Amikacin 3 842 3 478 (91) 3 885 3 522 (91) 0.84
Amoxicillin-clavulanic acid 3 845 2 462 (64) 3 870 2 456 (63) 0.60
Ampicillin/amoxicillin 3 834 614 (16) 3 823 595 (16) 0.59
Cefepime 3 668 2 785 (76) 3 750 2 825 (75) 0.55
Cefotaxime/ceftriaxone 3 752 2 798 (75) 3 835 2 874 (75) 0.71
Ceftazidime 3 780 2 869 (76) 3 791 2 848 (75) 0.43
Ciprofloxacin 3 815 2 818 (74) 3 720 2 756 (74) 0.83
Co-trimoxazole NT NT NT NT -
Doripenem NT NT NT NT -
Ertapenem 3 552 3 518 (99) 3 659 3 645 (100) <0.01*
Gentamicin 3 864 3 168 (82) 3 872 3 175 (82) 0.99
Imipenem 3 727 3 705 (99) 3 774 3 757 (100) 0.40
Meropenem 3 716 3 691 (99) 3 810 3 791 (100) 0.32
Piperacillin-tazobactam 3 485 3 020 (87) 3 736 3 237 (87) 0.99
   
Private Amikacin 2 781 2 598 (93) 4 040 3 725 (92) 0.06
Amoxicillin-clavulanic acid 2 780 1 945 (70) 4 171 2 791 (67) 0.01
Ampicillin/amoxicillin 1 998 425 (21) 2 310 466 (20) 0.38
Cefepime 2 778 2 283 (82) 4 040 3 254 (81) 0.09
Cefotaxime/ceftriaxone 2 777 2 253 (81) 4 171 3 329 (80) 0.18
Ceftazidime 2 148 1 755 (82) 2 804 2 231 (80) 0.06
Ciprofloxacin 1 997 1 378 (69) 3 534 2 301 (65) <0.01
Co-trimoxazole 1 746 657 (38) 2 298 839 (37) 0.47
Doripenem 2 753 2 748 (100) 4 013 4 007 (100) 0.75
Ertapenem 2 779 2 769 (100) 4 041 4 026 (100) 0.94
Gentamicin 2 779 2 368 (85) 4 045 3 448 (85) 0.97
Imipenem 2 777 2 772 (100) 4 043 4 033 (100) 0.61
Levofloxacin 792 593 (75) 1 229 868 (71) 0.04
Meropenem 2 780 2 777 (100) 4 042 4 034 (100) 0.54
Piperacillin-tazobactam 2 774 2 212 (80) 3 677 2 868 (78) 0.09
NT = not tested.
*Significance was based on low number of non-susceptible isolates.
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Table 2. Antimicrobial susceptibility patterns of Klebsiella pneumoniae isolates identified from blood cultures in South Africa, 2016 - 2017
Health sector Drug
2016 2017
p-value
Total 
isolates 
tested, N
Susceptible, 
n (%)
Total isolates 
tested, N Susceptible, n (%)
Public Amikacin 5 288 4 278 (81) 5 130 4 164 (81) 0.73
Amoxicillin-clavulanic acid 5 284 1 763 (33) 5 085 1 542 (30) <0.01
Cefepime 5 164 1 687 (33) 5 012 1 548 (31) 0.05
Cefotaxime/ceftriaxone 5 192 1 631 (31) 5 008 1 483 (30) 0.05
Ceftazidime 5 201 1 661 (32) 5 042 1 523 (30) 0.06
Ciprofloxacin 5 280 3 479 (66) 4 893 3 128 (64) 0.04
Co-trimoxazole NT NT NT NT -
Doripenem NT NT NT NT -
Ertapenem 4 769 4 562 (96) 4 696 4 333 (92) <0.01
Gentamicin 5 308 2 083 (39) 5 125 1 992 (39) 0.70
Imipenem 5 071 4 800 (95) 4 929 4 492 (91) <0.01
Levofloxacin 48 35 (73) 38 22 (58) 0.14
Meropenem 5 068 4 772 (94) 4 967 4 537 (91) <0.01
Piperacillin-tazobactam 4 967 2 799 (56) 4 951 2 718 (55) 0.15
Private Amikacin 2 444 1 964 (80) 3 162 2 392 (76) <0.01
Amoxicillin-clavulanic acid 2 450 975 (40) 3 175 1 133 (36) <0.01
Cefepime 2 435 1 070 (44) 3 167 1 231 (39) <0.01
Cefotaxime/ceftriaxone 2 442 1 052 (43) 3 169 1 203 (38) <0.01
Ceftazidime 1 760 789 (45) 2 307 895 (39) <0.01
Ciprofloxacin 2 068 1 231 (60) 2 824 1 528 (54) <0.01
Co-trimoxazole 1 853 789 (43) 2 625 1 027 (39) 0.02
Doripenem 2 376 2 185 (92) 3 047 2 683 (88) <0.01
Ertapenem 2 419 2 056 (85) 3 124 2 403 (77) <0.01
Gentamicin 2 442 1 405 (58) 3 169 1 727 (54) 0.02
Imipenem 2 410 2 175 (90) 3 121 2 647 (85) <0.01
Levofloxacin 509 382 (75) 551 378 (69) 0.02
Meropenem 2 431 2 206 (91) 3 123 2 679 (86) <0.01
Piperacillin-tazobactam 2 443 1 050 (43) 3 169 1 184 (37) <0.01
NT = not tested.
Table 3. Antimicrobial susceptibility patterns of Acinetobacter baumannii isolates identified from blood cultures in South Africa, 2016 - 2017
Health sector Drug
2016 2017
p-value
Total 
isolates 
tested, N
Susceptible, 
n (%)
Total isolates 
tested, N Susceptible, n (%)
Public Amikacin 2 064 913 (44) 2 052 765 (37) <0.01
Doripenem NT NT NT NT
Gentamicin 2 629 837 (32) 2 955 668 (23) <0.01
Imipenem 2 581 684 (27) 2 865 558 (19) <0.01
Meropenem 2 602 654 (25) 2 928 549 (19) <0.01
Minocycline 30 6 (20) 33 9 (27) 0.56
Tigecycline 1 279 1 176 (92) 1 745 1 585 (91) 0.28
Private Amikacin 288 182 (63) 439 249 (57) 0.08
Doripenem 275 120 (44) 435 172 (40) 0.28
Gentamicin 303 161 (53) 458 212 (46) 0.06
Imipenem 304 139 (46) 458 174 (38) 0.03
Meropenem 303 133 (44) 458 173 (38) 0.09
Minocycline NT NT NT NT -
Tigecycline 212 190 (90) 326 285 (87) 0.44
NT = not tested.
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P. aeruginosa demonstrated significant increases in susceptibility to 
piperacillin/tazobactam and ceftazidime in the private sector, which 
may be explained by the infrequent use of these agents as empirical 
treatment.
Equally, we are seeing changing patterns in susceptibility to 
penicillinase-stable penicillins in S. aureus in both sectors, with 
subsequent reduced rates of methicillin-resistant S. aureus (MRSA). 
Absolute numbers of S. aureus did not decline, suggesting that the 
decrease in MRSA proportions may be due to a strain replacement 
with Gram-negative organisms in the proportion of hospital-acquired 
infections, a decrease in the prevalence of particularly pathogenic 
MRSA clones, or a combination of these two factors. The widening 
gap in MRSA proportions between the two sectors over the 2 years 
suggests that these factors are operating to different extents in the 
two sectors.
The second GLASS report presented AMR data from nine 
countries in the African region. Nigeria reported data on E. coli 
and K. pneumoniae showing <25% susceptibility to third-generation 
cephalosporins from three sentinel sites, similar to our results 
for K. pneumoniae but not for E. coli. In contrast, susceptibility 
to third-generation cephalosporins in the UK is much higher, at 
90% for both organisms in 2017.[9] AST findings for the ESKAPE 
organisms reported from the public sector in the present study were 
comparable to findings from an SA study published in 2018.[10] In 
the present study, K. pneumoniae showed decreased susceptibility 
to carbapenems over the 2-year period, but susceptibility in isolates 
Table 4. Antimicrobial susceptibility patterns of Pseudomonas aeruginosa isolates identified from blood cultures in South Africa, 2016 - 2017
Health sector Drug
2016 2017
p-value
Total 
isolates 
tested, N
Susceptible, 
n (%)
Total isolates 
tested, N Susceptible, n (%)
Public Cefepime 1 076 884 (82) 1 324 1 119 (85) 0.12
Ceftazidime 1 150 906 (79) 1 404 1 173 (84) <0.01
Doripenem NT NT NT NT -
Imipenem 1 102 845 (77) 1 362 1 040 (76) 0.85
Meropenem 1 123 873 (78) 1 372 1 063 (77) 0.88
Piperacillin/tazobactam 1 118 812 (73) 1 369 1 112 (81) <0.01
Private Cefepime 908 652 (72) 1 240 862 (70) 0.25
Ceftazidime 892 657 (74) 1 228 876 (71) 0.24
Doripenem 883 601 (68) 1 208 762 (63) 0.02
Imipenem 911 567 (62) 1 243 719 (58) 0.04
Meropenem 912 588 (64) 1 244 745 (60) 0.03
Piperacillin/tazobactam 902 582 (65) 1 226 780 (64) 0.67
NT = not tested.
Table 5. Antimicrobial susceptibility patterns of Enterococcus faecium isolates identified from blood cultures in South Africa, 2016 - 2017
Health sector Drug
2016 2017
p-value
Total 
isolates 
tested, N
Susceptible, 
n (%)
Total isolates 
tested, N Susceptible, n (%)
Public Daptomycin NT NT NT NT -
Linezolid 1 380 1 369 (99) 1 236 1 224 (99) 0.64
Penicillin/ampicillin 837 30 (4) 813 46 (6) 0.05
Teicoplanin 1 033 1 001 (97) 908 853 (94) <0.01
Vancomycin 1 636 1 560 (95) 1 509 1 436 (95) 0.80
   
Private Daptomycin 65 63 (97) 104 102 (98) 0.64
Linezolid 215 210 (98) 191 190 (99) 0.22
Penicillin/ampicillin 38 3 (8) 27 0 0.26
Teicoplanin 295 283 (96) 299 282 (94) 0.36
Vancomycin 309 295 (95) 312 294 (94) 0.49
NT = not tested.
Table 6. Antimicrobial susceptibility patterns of Staphylococcus aureus isolates identified from blood cultures in South Africa, 2016 - 2017
Health sector Drug
2016 2017
p-valueTotal isolates tested, N Susceptible, n (%) Total isolates tested, N Susceptible, n (%)
Public Cloxacillin 5 118 3 705 (72) 5 108 3 951 (77) <0.01
Private Cloxacillin 1 283 950 (74) 1 508 1 283 (85) <0.01
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reported from secondary and tertiary health facilities from 2015 to 
2016 remained constant.[10] A. baumannii showed a notable decrease 
in susceptibility to the aminoglycosides: amikacin from 50% in 2015 
to 40% in 2016 and gentamicin from 32% in 2015 to 28% in 2016.[10] 
A decrease in susceptibility to teicoplanin was noted for E. faecium 
in the present study; however, susceptibility in isolates reported from 
the earlier study showed no change (97%) from 2015 to 2016. [10] 
Changing AST patterns to penicillinase-stable penicillins were also 
noted for S. aureus isolates. Both the present study and the earlier 
study showed increased susceptibility.[10,11]
This report indicates the importance of antimicrobial resistance 
surveillance for clinical treatment guidelines at the national level. At 
facility level there is a need for local antimicrobial susceptibility data 
to address antibiotic treatment appropriately. Specimen submission 
practices are important when addressing and analysing antimicrobial 
susceptibility patterns at each facility.
Study limitations
Findings from this study should be interpreted with caution. Its 
limitations have been highlighted in previous reports.[9,10] Briefly, 
these include: 
• Data may have been incomplete owing to missing information 
not captured on the laboratory information system or non-
standardised coding of ESKAPE organisms and antimicrobial 
agents at diagnostic laboratories.
• Testing methods and microbiological practice may have varied 
between laboratories, which could account for variations in the 
results presented in this report.
• Confirmatory AST methods were not performed or recorded for 
any of the ESKAPE organisms, as the results presented here were 
reported as captured on the laboratory information system by 
diagnostic laboratories. We have not been able to report on colistin 
AST, as new methods have been recommended by the CLSI and 
EUCAST guidelines, which were not universally implemented by 
all diagnostic laboratories during the period of the study.
• Data from the private sector represent a small (25 - 30%) 
proportion of the general population and may not be directly 
comparable with the much greater proportion in the public 
sector owing to factors such as selective testing, specimen-taking 
practices, infection control practices and patient populations that 
may differ between the two sectors.
• Vancomycin non-susceptibility for S. aureus requires confirmatory 
testing, which is not available at routine laboratory level. All 
S. aureus isolates that are non-susceptible to vancomycin should be 
referred to reference laboratories for confirmation.
• Results for carbapenemase-producing Enterobacteriaceae are not 
available in this report, as not all CRE isolates are tested for 
carbapenemase-producing genes.
• AST results for Enterobacter spp. were not reported in this study.
Conclusions
This study provides important laboratory data to monitor AST 
profiles of ESKAPE organisms. The key clinically important 
finding is the rapidly decreasing carbapenem susceptibility among 
Enterobacteriaceae reported in SA, irrespective of sector.  High 
numbers and rates of resistance in A. baumannii are alarming in the 
public sector as this drives the use of colistin, the last resource for 
treatment of multidrug-resistant organisms. In addition, the study 
provides baseline surveillance data that can be used to monitor the 
effectiveness of interventions implemented at a national level under 
the guidance and direction of the national AMR framework.
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